These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25604093)

  • 1. Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time.
    Zhou M; Bracci PM; McCoy LS; Hsuang G; Wiemels JL; Rice T; Zheng S; Kelsey KT; Wrensch MR; Wiencke JK
    Int J Cancer; 2015 Aug; 137(4):826-36. PubMed ID: 25604093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy.
    Wei Y; Wang T; Song H; Tian L; Lyu G; Zhao L; Xue Y
    J Surg Res; 2017 May; 211():266-278. PubMed ID: 28501127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
    Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
    Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
    Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
    J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
    Lin Y; Jiang T; Zhou K; Xu L; Chen B; Li G; Qiu X; Jiang T; Zhang W; Song SW
    Neuro Oncol; 2009 Oct; 11(5):468-76. PubMed ID: 19164435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.
    Trédan O; Manuel M; Clapisson G; Bachelot T; Chabaud S; Bardin-dit-Courageot C; Rigal C; Biota C; Bajard A; Pasqual N; Blay JY; Caux C; Ménétrier-Caux C
    Eur J Cancer; 2013 May; 49(7):1673-82. PubMed ID: 23265706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the potential of circulating hTERT levels in glioma: can plasma levels serve as an independent prognostic marker?
    Gandhi P; Khare R; Garg N
    J Neurooncol; 2017 Nov; 135(2):255-261. PubMed ID: 28756592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner.
    Birner P; Tchorbanov A; Natchev S; Tuettenberg J; Guentchev M
    J Clin Pathol; 2015 Oct; 68(10):830-4. PubMed ID: 26109200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
    Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
    Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients.
    Wertel I; Surówka J; Polak G; Barczyński B; Bednarek W; Jakubowicz-Gil J; Bojarska-Junak A; Kotarski J
    Tumour Biol; 2015 Jun; 36(6):4811-7. PubMed ID: 25647263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage CCL22 expression in the tumor microenvironment and implications for survival in patients with squamous cell carcinoma of the tongue.
    Kimura S; Nanbu U; Noguchi H; Harada Y; Kumamoto K; Sasaguri Y; Nakayama T
    J Oral Pathol Med; 2019 Sep; 48(8):677-685. PubMed ID: 31134686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of CCL22 and mutated NOTCH1 in tongue and mouth floor squamous cell carcinoma results in decreased Th2 cell recruitment and expression, predicting poor clinical outcome.
    Li X; Liu Z; Zhou W; Liu X; Cao W
    BMC Cancer; 2021 Aug; 21(1):922. PubMed ID: 34391381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Plasma Levels of the TH2 chemokine CCL18 associated with low CD4+ T cell counts in HIV-1-infected Patients with a Suppressed Viral Load.
    Malhotra P; Haslett P; Sherry B; Shepp DH; Barber P; Abshier J; Roy U; Schmidtmayerova H
    Sci Rep; 2019 Apr; 9(1):5963. PubMed ID: 30979916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.
    Han S; Zhang C; Li Q; Dong J; Liu Y; Huang Y; Jiang T; Wu A
    Br J Cancer; 2014 May; 110(10):2560-8. PubMed ID: 24691423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.